Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva’s Pay-For-Delay Settlement Restricts Brand-Generic Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

$1.2 billion agreement resolving Provigil litigation with FTC blocks Teva from entering business deal with competitor until 30 days after patent settlement that restricts generic entry, sets $7 million cap on litigation savings.

You may also be interested in...



Namenda Product Hopping Settlement Surpasses Most Recent DOJ Agreements

Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.

Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals

Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.

FTC Wins $448M Ruling Against AbbVie For Sham Litigation Rather Than Pay-For-Delay Deal

Court finds AbbVie used sham litigation to maintain its monopoly on AndroGel but denies FTC request for an injunction; it is the largest monetary award in a litigated FTC antitrust case.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078525

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel